Download PDF
Thromb Haemost 1993; 70(04): 562-567
DOI: 10.1055/s-0038-1649627
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Orgaran (Org 10172) or Heparin for Preventing Venous Thrombosis after Elective Surgery for Malignant Disease? A Double-Blind, Randomised, Multicentre Comparison

A Gallus
1   The Flinders Medical Centre, Adelaide, Australia
,
J Cade
2   The Royal Melbourne Hospital and Austin Hospitals, Melbourne, Australia
,
P Ockelford
3   The Middlemore Hospital, Auckland, New Zealand
,
S Hepburn
4   The Oraganon Australia
,
M Maas
5   Medical Research and Development Unit, Organon International, Oss, The Netherlands
,
H Magnani
5   Medical Research and Development Unit, Organon International, Oss, The Netherlands
,
T Bucknall
2   The Royal Melbourne Hospital and Austin Hospitals, Melbourne, Australia
,
J Stevens
1   The Flinders Medical Centre, Adelaide, Australia
,
F Porteous
3   The Middlemore Hospital, Auckland, New Zealand
,
(ANZ-Organon Investigators’Group) › Author Affiliations
Further Information

Publication History

Received 18 January 1992

Accepted after revision 18 May 1993

Publication Date:
24 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

This double-blind, randomised, multicentre trial in 513 patients having elective surgery for intra-abdominal or intrathoracic malignancy compared the efficacy and safety of venous thrombosis (VT) prophylaxis using 750 anti-factor Xa units of Orgaran (a mixture of low molecular weight heparinoids) given subcutaneously (sc) twice-daily with that of twice-daily injections of 5,000 units Standard heparin. The main study endpoints were the development of postoperative VT detected by 125I-fibrinogen leg scanning, and the onset of clinically significant venous thromboembolism or bleeding. “Intent to treat” analysis showed a statistically non-significant trend towards less VT during Orgaran prophylaxis (10.4%) than after heparin (14.9%) and there was no difference in bleeding complications between the two study groups. Results remained similar if only patients who completed the intended course of therapy (“compliant patients”) were analysed. Other trials have shown that Orgaran prevents VT after hip surgery and stroke. We now show it is also safe and effective in patients having major surgery for cancer.

 

  • References

  • 1 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopaedic, and urologic surgery. New Engl J Med 1988; 318: 1162-1173
    CrossrefPubMedGoogle Scholar
  • 2 Clagett GP, Reisch JS. Prevention of venous thomboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988; 208: 227-240
    CrossrefPubMedGoogle Scholar
  • 3 Strand L, Bank-Mikkelsen OK, Lindewald H. Small heparin doses as prophylaxis against deep-vein thrombosis in major surgery. Acta Chir Scand 1975; 141: 624-627
    PubMedGoogle Scholar
  • 4 Rem J, Duckert F, Fridrich R, Gruber UF. Subkutane kleine Heparindosen zur Thromboseprophylaxe in der allgemeinen Chirurgie und Urologie. Schweiz Med Wschr 1975; 105: 827-835
    PubMedGoogle Scholar
  • 5 Gallus AS, Hirsh J, O‗Brien EO, McBride JA, Tuttle RJ, Gent M. Prevention of venous thrombosis with small, subcutaneous doses of heparin. J Am Med Assoc 1976; 235: 1980-1982
    CrossrefPubMedGoogle Scholar
  • 6 Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 1983; 145: 606-613
    CrossrefPubMedGoogle Scholar
  • 7 Rogers PH, Walsh PN, Marder VJ. et al. Controlled trial of low-dose heparin and sulfinpyrazone to prevent venous thromboembolism after operation on the hip. J Bone Joint Surg 1978; 60-A: 758-762
    PubMedGoogle Scholar
  • 8 Planes A, Vochelle N, Mazas F. et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemostas 1988; 60: 407-410
    PubMedGoogle Scholar
  • 9 Moskovitz PA, Ellenberg SS, Feffer HL. et al. Low-dose heparin in the prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg 1978; 60-A: 1065-1070
    PubMedGoogle Scholar
  • 10 Chong BH. Heparin-induced thrombocytopenia. Blood Rev 1988; 2: 108-114
    CrossrefPubMedGoogle Scholar
  • 11 Hirsh J, Levine MN. Low molecular weight heparins. Blood 1992; 79: 1-17
    PubMedGoogle Scholar
  • 12 Cade JF, Buchanan MR, Boneu B. et al. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984; 35: 613-625
    CrossrefPubMedGoogle Scholar
  • 13 Bang CJ, Berstad A, Talstad I. Gastric mucosal bleeding after unfractionated and low molecular weight heparin in rats. Scand J Gastroenterol 1990; 25: 379-382
    CrossrefPubMedGoogle Scholar
  • 14 Cadroy Y, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with Standard heparin. J Lab Clin Med 1989; 114: 349-357
    PubMedGoogle Scholar
  • 15 Levine MN, Hirsh J, Gent M. et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114: 545-551
    CrossrefPubMedGoogle Scholar
  • 16 Meuleman DG, Hobbelen PMJ, van Dedem G, Moelker HCT. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models. Thromb Res 1982; 27: 353-363
    CrossrefPubMedGoogle Scholar
  • 17 Boneu B, Buchanan MR, Cade JF. et al. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res 1985; 40: 81-89
    CrossrefPubMedGoogle Scholar
  • 18 Hobbelen PMJ, Vogel GMT, Meuleman DG. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factor Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats. Thromb Res 1987; 48: 549-558
    CrossrefPubMedGoogle Scholar
  • 19 Cade JF, Wood M, Magnani H, Westlake GW. Early clinical experience of a new heparinoid, Org 10172, in prevention of venous thrombosis. Thromb Res 1987; 45: 497-503
    CrossrefPubMedGoogle Scholar
  • 20 Kaplan AL, Meier P. Non-parametric estimation from incomplete values. J Am Stat Assoc 1958; 53: 457-481
    CrossrefPubMedGoogle Scholar
  • 21 Kalbfleisch JD, Prentice RL. (eds) The Statistical Analysis of Failure Time Data. New York: J Wiley & Sons; 1980
    Google Scholar
  • 22 Rohlf FJ, Sokal RR. Statistical Tables. 2.. San Francisco: W. H. Freeman and Company; 1981
    Google Scholar
  • 23 Connolly SJ, Laupacis A, Gent M. et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-355
    CrossrefPubMedGoogle Scholar
  • 24 Blum A, Desruennes E, Elias A, Lagrange G, Loriferne JF. DVT prophylaxis in surgery for digestive tract cancer comparing the LMW heparinoid Org 10172 (Lomoparan) with calcium heparin. Thromb Haemostas 1989; 62 (Suppl. 00) 126
    PubMedGoogle Scholar
  • 25 Fricker J-P, Vergnes Y, Schach R. et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Ivest 1988; 18: 561-567
    PubMedGoogle Scholar
  • 26 Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial. Thromb Haemostas 1988; 59: 216-220
    PubMedGoogle Scholar
  • 27 Bergqvist D, Burmark AS, Frisell J. et al. Low molecular weight heparin once daily compared with conventional low dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-208
    CrossrefPubMedGoogle Scholar
  • 28 Bergqvist D, Matzsch T, Burmark AS. et al. Low molecular weight heparin given the evening before surgery compared with conventional low dose heparin in prevention of thrombosis. Br J Surg 1988; 75: 888-891
    CrossrefPubMedGoogle Scholar
  • 29 Hartl P, Brucke P, Dienstl E, Vinazzer H. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res 1990; 57: 577-584
    CrossrefPubMedGoogle Scholar
  • 30 Bergqvist D, Burmark AS, Frisell J. et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin. Semin Thromb Hemostas 1990; 16 (Suppl. 00) 19-24
    PubMedGoogle Scholar
  • 31 Samama M, Bernard JP, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988; 75: 128-131
    CrossrefPubMedGoogle Scholar
  • 32 Kakkar VV, Murray WJG. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thromboembolism: a co-operative study. Br J Surg 1985; 72: 786-791
    CrossrefPubMedGoogle Scholar
  • 33 Encke A, Breddin K. Comparison of low molecular weight heparin and unfractionated heparin for the prevention of deep vein throm-bosis in patients undergoing abdominal surgery. Br J Surg 1988; 75: 1058-1063
    CrossrefPubMedGoogle Scholar
  • 34 Hoek JA, Henny ChP, Knipscheer HC, ten Cate H, Nurmohammed MT, ten Cate JW. The effect of different anaesthetic techniques on the incidence of thrombosis following total hip replacement. Thromb Haemostas 1991; 65: 122-125
    PubMedGoogle Scholar
  • 35 Hoek JA, Nurmohammed MT, Hamelynck KJ. et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoids. Thromb Haemostas 1992; 67: 28-32
    PubMedGoogle Scholar
  • 36 Gallus AS. Anticoagulants in the prevention of venous thromboembolism. Clin Haematol 1990; 3: 651-684
    PubMedGoogle Scholar
  • 37 Turpie AGG, Levine MN, Hirsh J. et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987; i: 524-526
    PubMedGoogle Scholar
  • 38 Turpie AGG, Gent M, Côte R. et al. A low molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Ann Intern Med 1992; 117: 353-357
    CrossrefPubMedGoogle Scholar